Board of Directors

Peter Nielsen, President, CEO, CFO, and Chairman of the Board of Directors:

Peter Nielsen co-founded Bio-Path Holdings, a public biotechnology company developing targeted oncology therapies, and currently serves as Bio-Path’s president, chief executive officer, chief financial officer, and chairman of the board of directors. At the time of Bio-Path’s establishment in 2007, Mr. Nielsen licensed technology and targets from the University of Texas M.D. Anderson Cancer Center and coordinated pre-clinical development, optimization and manufacturing of Bio-Path’s lead product, BP1001. Over the next ten years, Mr. Nielsen led the clinical advancement of BP1001 into Phase 2 studies, the introduction of additional pipeline candidates, and the company’s public market debut. Prior to co-founding Bio-Path, Mr. Nielsen has worked with several other companies, leading turnarounds and developing and executing on strategies for growth. He currently serves as a director of Bio-Path and of Synthecon, Inc., a company developing 3D cell culture technology. Before entering the biotechnology sector, Mr. Nielsen was a lieutenant in the U.S. Naval Nuclear Power program where he was director of the physics department, and was employed at Ford Motor Company in product development. Mr. Nielsen has a broad background in senior management and has significant negotiating experience. He has earned degrees in engineering, mathematics and an MBA in finance from the University of California at Berkeley.

Michael Garrison

Mr. Garrison is a principal and president of Body Sculpt International, LLC, which operates plastic surgery clinics under the trade name Sono Bello. Prior to founding Body Sculpt International, Mr. Garrison spent 10 years in a variety of executive roles with Dell, Inc., most recently as director of marketing in the Americas Small and Medium Business division. Previously, Mr. Garrison held general management and corporate development positions with ITT Industries, a leading industrial manufacturer. Mr. Garrison holds a Master of Business Administration from Harvard Business School and a Bachelor of Science in mechanical engineering from Purdue University.

Amy Sing, M.D.

Dr. Sing has served as a director of Bio-Path since November 2014. She served as the senior medical director for U.S. medical affairs from January 2011 until August 2016 at Genomic Health, Inc., a leading publicly held biotechnology company that assists physicians and patients in making personalized cancer treatment decisions. From 2004 to 2006, Dr. Sing led oversight of the approved breast cancer drug Avastin Investigator Sponsored Trials (IST) program at Genentech, Inc., a member of the Roche Group, providing major contributions to the understanding and development of cancer research. From 2004 to 2011, Dr. Sing worked in various other leadership and research positions at Genentech, Inc. Dr. Sing also led research teams for Seattle Genetics, Inc. from 1999 to 2003 and has received awards from the National Cancer Institute, American Cancer Society and Stanford University. Dr. Sing received a Bachelor of Arts from Amherst College and a medical degree from Stanford University.

Heath Cleaver

Mr. Cleaver has served as chief financial officer of Porto Energy Corp., junior oil and gas exploration company listed on the Canadian Venture Exchange, since February 2011. Prior to his elevation to chief financial officer, Mr. Cleaver served as chief accounting officer. Mr. Cleaver served as corporate controller and then as vice president and chief accounting officer for BPZ Energy from October 2006 to mid-2010. Prior to joining BPZ, Mr. Cleaver was engaged as a consultant for a variety of public companies such as Rosetta Resources, Calpine Natural Gas and Index Oil and Gas. Mr. Cleaver is a Certified Public Accountant in the state of Texas and holds a Bachelor of Business Administration - Accounting from Texas A&M University.

Douglas P. Morris

Doug Morris is a co-founder of Bio-Path and a co-founding director. Mr. Morris has a number of administrative responsibilities, including working with retail broker/dealers in raising capital for small cap companies, and interfacing with existing shareholders. Mr. Morris has a Bachelor of Arts from Brigham Young University and a Master of Public Administration from the University of Southern California.